Brought to you by 
Xenova forms MetaXen US subsidiary, provides $1mm Series A funding
07 Apr 2016
Executive Summary
Xenova and three individual founders provided $1mm in Series A capitalization to form a new drug discovery company called MetaXen. Xenova will keep a majority ownership in the company and provide additional funding in the future.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Xenova forms MetaXen US subsidiary, provides $1mm Series A funding
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice